What Prescribers Should Know About the PT-141 Peptide

A patient who asks about the PT-141 peptide is asking about bremelanotide, a synthetic seven-amino-acid peptide that activates melanocortin receptors. PT-141 was its development code name. The form approved by the FDA in 2019 is a subcutaneous injection for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Compounded versions, including nasal sprays, are not approved by the FDA. MediVera Compounding Pharmacy™ prepares PT-141 (Bremelanotide) as a compounded nasal spray, by prescription. Whether it suits a specific patient is a clinical question, one the prescribing provider weighs against the record below.

PT-141 Peptide at a Glance

  • Approved product. A subcutaneous injection for acquired, generalized HSDD in premenopausal women, approved June 21, 2019.
  • Contraindications. Uncontrolled hypertension and known cardiovascular disease, per the approved label.
  • Nasal history. The developer ended nasal work as a first-line therapy, citing blood pressure rises and variable uptake.
  • Compounded spray. Prepared by prescription for an individual patient, without FDA approval.

The Approved Drug Behind the PT-141 Peptide

Bremelanotide’s approval came on June 21, 2019, under NDA 210557, which the FDA classified as a new molecular entity. The developer, Palatin Technologies, sponsored the phase 3 trials. Palatin later licensed North American rights to AMAG Pharmaceuticals, which filed the application.

The prescribing information approved in 2019 covers premenopausal women with acquired, generalized HSDD, where low sexual desire causes marked distress or interpersonal difficulty. The low desire must not stem from a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or drug. Postmenopausal women and men fall outside the indication, as does use to improve sexual performance.

FormBremelanotide acetate solution in a single-dose autoinjector.
Dose1.75 mg/0.3 mL injected under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity.
FrequencyNo more than one dose within 24 hours, and more than 8 doses a month is not recommended.
Stop ruleDiscontinue after 8 weeks if the patient reports no improvement in her symptoms.
StatusMarketed by prescription, as of October 2026.
What the approved label sets

Regulatory status

A compounded bremelanotide nasal spray is not FDA-approved. Bremelanotide itself is the active ingredient of an FDA-approved subcutaneous product for one indication. Compounded medications are prepared on a healthcare provider’s prescription to meet individual patient needs, and the label facts above do not transfer to them.

What Section 503A Requires Before Bremelanotide Is Compounded

Section 503A (21 U.S.C. 353a) covers drugs compounded for an identified individual patient on a valid prescription. A drug that qualifies is exempt from three FD&C Act sections, among them the requirement for new drug approval. The exemption is the reason a compounded drug carries no FDA approval.

Each bulk drug substance needs a valid certificate of analysis and a source registered with the FDA. It must also meet an applicable USP or National Formulary monograph or, where none exists, be a component of an approved drug. Bremelanotide is the active ingredient of an approved drug, which is one of the bases on which a bulk drug substance can qualify for compounding under Section 503A. MediVera sources its bremelanotide from an FDA-registered facility, with a certificate of analysis for each lot. An interim HHS policy from October 2026 covers six other peptides, and PT-141 is not one of them.

Section 503A also limits copies. To qualify, the pharmacy must not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available drug. A drug changed for an identified patient is not essentially a copy when the prescriber determines the change makes a significant difference for that patient.

FDA’s compounding questions and answers set out a related position. Compounded drugs should be used only when an approved drug cannot meet a patient’s medical needs. The prescriber who writes the prescription makes both calls, applying that position and the significant-difference determination to one patient.

How Bremelanotide Acts on Melanocortin Receptors

Bremelanotide, the PT-141 peptide, is a nonselective melanocortin receptor agonist. MC1R ranks first in order of potency, then MC4R, MC3R, MC5R and MC2R, and MC1R and MC4R binding is most relevant at therapeutic doses. Neurons in many areas of the central nervous system express MC4R, and melanocytes express MC1R, where binding increases pigmentation.

The label calls bremelanotide’s mechanism in HSDD unknown. FDA’s multidisciplinary review of the application called the mechanism of action in humans speculative and said none had been established for HSDD in females. Hypotheses about the brain pathway involved come from animal studies.

In female rats, bremelanotide increased solicitation behavior after subcutaneous dosing or infusion into the lateral ventricles or the medial preoptic area (mPOA). Rat data reviewed in 2007 suggested it may act by activating dopamine terminals there. A 2022 review whose authors included AMAG and Palatin employees drew a similar dopamine hypothesis from animal studies.

Why Development Moved Away From the Nasal Route

The first clinical studies of the PT-141 peptide in women used the intranasal route, as studies in men did, according to FDA reviewers. Phase 3 testing used subcutaneous injection instead. The review ties that shift to variable systemic exposure through the nose, and the developer’s own filings add blood pressure.

Palatin’s 2009 annual report describes significant variation in plasma levels among patients given nasal bremelanotide. Blood pressure rose in some of them, a rise Palatin called a significant factor in ending nasal work as a first-line therapy. In a phase 1 study, subcutaneous dosing significantly reduced the variation in plasma exposure.

In its nonclinical review, FDA adds that intranasal dosing yielded low and highly variable exposure. A nasal dose given in an alcohol-interaction study during development reached a mean peak blood level about 2.5 times higher than the approved injection. The current label reports that single comparison, which says nothing about how a compounded spray is absorbed or how it affects blood pressure.

August 2007FDA raised serious concerns about benefit and risk, named blood pressure increases its greatest safety concern, and did not support the proposed phase 3 erectile dysfunction studies, per Palatin’s filing.
May 2008Palatin announced it had discontinued development of bremelanotide for male and female sexual dysfunction.
September 2008Palatin’s annual report named blood pressure increases in some patients a significant factor in stopping bremelanotide as a first-line therapy.
2009Palatin’s annual report described developing subcutaneous bremelanotide and meeting FDA about phase 1 data supporting the switch.
March 2018The new drug application was submitted.
June 2019Approval followed for the subcutaneous injection.
Development dates from the record

Studies in Men in the Development Record

For men, the record on the PT-141 peptide is research history. FDA reviewers list erectile dysfunction in males among earlier development programs that did not lead to approved products. Palatin’s 2009 annual report describes phase 2B placebo-controlled trials of nasal bremelanotide for erectile dysfunction in 726 non-diabetic and 294 diabetic patients.

FDA questioned the program’s overall efficacy results and clinical benefit in 2007, according to Palatin’s filing. By 2009 Palatin was pursuing subcutaneous bremelanotide for both erectile dysfunction and female sexual dysfunction. The approval that followed covers premenopausal women alone, and the label states that it is not indicated for HSDD in men.

Phase 3 Results in Premenopausal Women

Two identical randomized, double-blind, placebo-controlled phase 3 trials, called RECONNECT, tested the PT-141 peptide in premenopausal women with HSDD. Each ran 24 weeks, with bremelanotide injected as needed. Their 2019 report in Obstetrics & Gynecology counts 1,267 women randomized, 1,247 in the safety population and 1,202 in the modified intent-to-treat efficacy population.

The trials shared two coprimary endpoints. Desire was scored on the Female Sexual Function Index desire domain, which runs from 1.2 to 6.0. Distress over low desire was scored 0 to 4 on item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.

Both endpoints differed significantly from placebo in each trial. Desire scores rose 0.30 and 0.42 points more than with placebo, and distress scores fell 0.37 and 0.29 points more. Pooled across both trials, the differences were 0.35 for desire and 0.33 for distress.

Satisfying sexual events, a secondary endpoint, did not differ significantly from placebo, the label adds. Early discontinuation of the double-blind period ran higher on bremelanotide, 40% against 13% in one trial and 39% against 25% in the other. Palatin and AMAG funded both trials.

A separate 2019 report in the same journal covers the 52-week open-label extension, which had no placebo group. Of 856 eligible women who completed the core trials, 684 enrolled and 272 finished it. All of its statistical analyses were descriptive.

Blood Pressure and Side Effects on the Approved Label

Every figure here comes from studies of the approved injection, and none transfers to a compounded nasal spray of the PT-141 peptide. The label lists uncontrolled hypertension and known cardiovascular disease as contraindications, and does not recommend use in patients at high cardiovascular risk.

Blood pressure rose transiently in clinical studies. Maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose. Heart rate fell by up to 5 beats per minute, and both measures usually returned to baseline within 12 hours.

The label’s second warning concerns pigmentation, which fits MC1R’s role on melanocytes. In phase 3, 1% of patients using up to 8 doses a month developed focal hyperpigmentation, against none on placebo. In a separate clinical study of daily dosing for 8 days, 38% developed it.

Nausea led the adverse reactions in phase 3, at 40% of treated patients. Incidence peaked after the first dose, at 21%, then fell to about 3% with later doses, and 13% needed an anti-emetic. Flushing followed at 20.3%, against 0.3% on placebo.

The label’s other common reactions, above 4%, were injection-site reactions, headache and vomiting. One case of acute hepatitis followed 10 doses over a year in the open-label extension, and a drug role could not be excluded. Adverse reactions led 18% of treated patients to stop, against 2% on placebo.

Cautions to Weigh Before Prescribing a Compounded Spray

No nasal form of the PT-141 peptide is approved. None of the sources cited here gives a human bioavailability figure for the nasal route. None concludes that a compounded spray matches the injection in safety or effect, or can stand in for it.

The choice for a specific patient therefore rests with the prescriber, who judges that patient’s needs against the record as it stands. For the injection, the label asks prescribers to weigh cardiovascular risk before starting and periodically during treatment, and to confirm blood pressure is well controlled. Whether these cautions apply to a compounded spray is a clinical judgment.

The label also flags two interactions. Bremelanotide may slow gastric emptying and so reduce absorption of oral medicines taken with it. Use with oral naltrexone products for alcohol or opioid addiction should be avoided, the label says, given the severe consequence of treatment failure.

The label links higher doses to more nausea, focal hyperpigmentation and larger blood pressure rises. In its data, patients with dark skin were more likely to develop focal hyperpigmentation, and resolution after stopping was not confirmed in all. In severe kidney impairment, with eGFR under 30, the label advises caution, since adverse reactions may be more frequent and severe.

Prescribing PT-141 (Bremelanotide)

The decision on a compounded spray for one patient stays with the prescriber. Once it is made, the provider portal is where the prescription goes, whether by e-prescribing, fax, phone, online submission or a paper prescription. Every partner also gets a dedicated account manager.

MediVera Compounding Pharmacy™ ships to patients in 49 states and Puerto Rico, and most compounds ship within 48 hours of a valid prescription being received and verified. PT-141 (Bremelanotide) appears among the peptides the pharmacy lists as available, and the pharmacy’s accreditation and testing record can be reviewed before prescribing.

See the PT-141 (Bremelanotide) Page

Open the Provider Portal

Common Questions About the PT-141 Peptide

Is PT-141 the Same as Bremelanotide?

PT-141 and bremelanotide are two names for one synthetic peptide. FDA’s substance registry lists PT-141 free base as a synonym of bremelanotide, and its acetate record lists PT-141 too. FDA reviewers give PT-141 as Palatin’s development code name, and published research pairs the names, as in “bremelanotide (PT-141).”

What Class of Drug Is PT-141?

PT-141, or bremelanotide, is a melanocortin receptor agonist. Palatin, its developer, described it as a synthetic peptide analog of alpha-MSH, a naturally occurring hormone. FDA’s substance registry lists its formula as C50H68N14O10, and the label gives a molecular weight of 1025.2 as the free base.

What Does PT-141 Actually Do?

PT-141 binds and activates melanocortin receptors. FDA reviewers call it a nonselective, high-affinity agonist at MC1R, MC3R and MC4R. In rats, systemically given PT-141 activated hypothalamic neurons, but the label states that how the approved product improves HSDD in women is unknown.

Does PT-141 Require a Prescription?

Yes, the approved injection is marketed by prescription. Under section 503A, a compounded spray is prepared for an identified patient on a valid prescription. MediVera Compounding Pharmacy™ operates as a 503A pharmacy, so it prepares PT-141 (Bremelanotide) nasal spray only by prescription for an individual patient.

How Long Does PT-141 Take to Kick In?

The approved injection’s label calls for dosing at least 45 minutes before anticipated sexual activity. How long the effect lasts after each dose is unknown, the label states, and the best dosing window is not fully characterized. Median time to peak blood level after the injection is about 1 hour, and none of these timings applies to a compounded nasal spray.

Who Should Not Take PT-141?

For the approved injection, the label contraindicates bremelanotide in uncontrolled hypertension and known cardiovascular disease. Caution applies in severe kidney or liver impairment, and animal findings suggest potential fetal harm in pregnancy. Safety and effectiveness are not established in children or older adults.

What Safety Data Exist for PT-141 Nasal Spray?

The approved label’s adverse-event rates and warnings come from the injection trials, and it also reports intranasal doses studied during development. FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before marketing. With its own nasal formulation, the developer believed blood pressure rises, nausea and vomiting were at least partly due to variable drug uptake.

Is Bremelanotide Indicated in Men?

Bremelanotide is not indicated in men, according to the approved label. Two early studies by Palatin authors, published together in 2004, gave intranasal PT-141 to healthy men and to men with erectile dysfunction. Flushing and nausea were the most common adverse events in those studies.

Sources

  1. Bremelanotide injection, prescribing information approved June 2019. U.S. Food and Drug Administration, NDA 210557. FDA
  2. 21 U.S.C. 353a, Pharmacy compounding (Section 503A of the Federal Food, Drug, and Cosmetic Act). Legal Information Institute
  3. Compounding and the FDA, Questions and Answers. U.S. Food and Drug Administration. FDA
  4. Multidisciplinary Review and Evaluation, NDA 210557 (bremelanotide). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2019. FDA
  5. Pfaus J, et al. Bremelanotide, an overview of preclinical CNS effects on female sexual function. The Journal of Sexual Medicine, 2007. PubMed
  6. Pfaus JG, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 2022. PubMed
  7. Palatin Technologies, Inc. Annual report on Form 10-K for the fiscal year ended June 30, 2009. U.S. Securities and Exchange Commission, filed September 28, 2009. SEC
  8. Bremelanotide injection, current prescribing information. U.S. National Library of Medicine. DailyMed
  9. Palatin Technologies, Inc. Annual report on Form 10-K for the fiscal year ended June 30, 2007. U.S. Securities and Exchange Commission, filed September 13, 2007. SEC
  10. Palatin Technologies, Inc. Press release of May 13, 2008, filed as Exhibit 99 to Form 8-K. U.S. Securities and Exchange Commission. SEC
  11. Palatin Technologies, Inc. Annual report on Form 10-K for the fiscal year ended June 30, 2008. U.S. Securities and Exchange Commission, filed September 29, 2008. SEC
  12. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder, two randomized phase 3 trials. Obstetrics & Gynecology, 2019. PubMed
  13. Simon JA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics & Gynecology, 2019. PubMed
  14. Bremelanotide, UNII 6Y24O4F92S. U.S. Food and Drug Administration, Global Substance Registration System. GSRS
  15. Bremelanotide acetate, UNII PV2WI7495P. U.S. Food and Drug Administration, Global Substance Registration System. GSRS
  16. Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 2004. PubMed

This article is for informational purposes only and is not medical advice. Always consult a healthcare professional before starting any treatment. Compounded medications referenced are not reviewed by the FDA for safety or effectiveness and are prepared by prescription for individual patients. Providers are solely responsible for determining their appropriateness.

MV

MediVera MediVera Compounding Pharmacy

On this page

Gloved MediVera pharmacist loading a compounded vial into a laboratory mixing chamber

A Smarter Way to Handle Compounding

Private practices, specialty clinics, and high-volume prescribers choose MediVera because they need a pharmacy partner that doesn't slow them down. Dedicated account management, clinical education resources, easy prescription submission via fax, phone, or eScribe, and most compounds shipped within 48 hours. Your patients are taken care of without your staff having to chase down the pharmacy.

If you run a telehealth platform and need a compounding pharmacy licensed across multiple states, MediVera was built for this. We handle prescription fulfillment, patient communication, and clinical education so your team can focus on growing the platform. With nationwide licensing behind every order, your patients get a consistent, high-quality experience regardless of where they live.